<p>温哥华，不列颠哥伦比亚省 --（Newsfile Corp. -2026 年 5 月 13 日）- BetterLife Pharma Inc.（CSE: BETR）（OTCQB: BETRF）（FSE: NPAU）（&#34;BetterLife&#34;或&#34;公司&#34;），一家新兴生物科技公司，欣然宣布已任命 Doug Drysdale 为执行董事长和董事，Doug Drysdale 目前是 BetterLife 的企业顾问，曾任 Cybin Inc.（&#34;Cybin&#34;）（NYSE: CYBN）的首席执行官。</p>
<p>在 Cybin，Drysdale 先生领导了公司的战略和团队建设，使其在短短三年内从分子创始阶段发展到第三阶段临床试验。Drysdale 先生因其在多个演讲、座谈会和媒体采访中积极倡导通过革命性的方法改善心理健康而闻名。</p>
<p>&#34;我们很高兴欢迎 Doug 加入我们的董事会。他在全球领导力方面的卓越表现，凭借在不同市场和治疗领域成功执行多项交易的记录，带来了深厚的战略洞察力和运营专业知识，这将显著增强 BetterLife 的实力，&#34;BetterLife 的首席执行官 Ahmad Doroudian 表示。&#34;Doug 在复杂交易环境中导航和扩大机会的经验将对我们继续推进增长战略和创造长期股东价值至关重要。&#34;</p>
<p>Drysdale 先生评论道：&#34;我很高兴能以执行董事长和董事的身份加入 BetterLife。作为 Cybin 的领导者，我在短短三年内将其从分子创始阶段推进到第三阶段临床试验，我期待将这种执行专注和全球交易专业知识带入 BetterLife，以加速其增长战略。与团队一起，我们将继续推进针对神经系统疾病的创新疗法，为患者和股东创造长期价值。&#34;</p>
<p>根据 Drysdale 先生被任命为执行董事长的决定，公司已同意授予 Drysdale 先生购买 3,500,000 股 BetterLife 普通股的股票期权，行使价格为 0.065 美元，按月在 24 个月内归属，期限为十（10）年。</p>
<p><strong>关于 BetterLife Pharma</strong></p>
<p>BetterLife Pharma Inc.是一家新兴生物技术公司，主要专注于开发和商业化 BETR-001 以治疗各种神经系统疾病。BETR-001 目前处于临床前和 IND 启用研究阶段，是一种非致幻和非管制的 LSD 衍生物，其独特之处在于它不受监管，因此可以自我管理。BetterLife 对 BETR-001 的合成专利消除了监管障碍，其待批专利涵盖了各种神经系统疾病的治疗，预计有效期至 2042 年左右。</p>
<p>BetterLife 还拥有一种用于治疗病毒感染的药物候选者，并正在寻求进一步发展的战略选择。</p>
<p>有关更多信息，请访问 BetterLife Pharma。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>没有证券交易所审查或对本新闻稿内容的充分性或准确性承担责任。本新闻稿可能包含非历史事实的前瞻性声明。前瞻性声明通常通过&#34;将&#34;、&#34;可能&#34;、&#34;应该&#34;、&#34;预期&#34;、&#34;期望&#34;和类似表达来识别。除历史事实声明外，本发布中包含的所有声明均为前瞻性声明，涉及风险和不确定性。不能保证这些声明将被证明是准确的，实际结果和未来事件可能与这些声明中预期的有实质性差异。可能导致实际结果与公司预期有实质性差异的重要因素包括未能满足相关证券交易所的条件以及公司不时向证券监管机构提交的文件中详细列出的其他风险。读者应注意，准备任何前瞻性信息时所使用的假设可能被证明是错误的。事件或情况可能导致实际结果与预测有实质性差异，原因是众多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制范围。读者应谨慎对待任何前瞻性信息。尽管管理层在准备时认为这些信息是合理的，但可能被证明是错误的，实际结果可能与预期有实质性差异。本新闻稿中包含的前瞻性声明明确受到本警示说明的限制。本新闻稿中包含的前瞻性声明是在本新闻稿日期作出的，公司将根据适用法律的明确要求，公开更新或修订任何包含的前瞻性声明。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5696/297144_7bbd785a74da5989_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5696/297144_7bbd785a74da5989_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/297144</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297144/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297144/375"/></p>

2 倍做空纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

<p>BetterLife Pharma Inc. 任命 Doug Drysdale 为执行董事长和董事。Drysdale 曾是 Cybin Inc. 的首席执行官，以其在推进心理健康护理方面的领导能力而受到认可。他的任命旨在增强 BetterLife 的增长战略，特别是在开发神经系统疾病的创新疗法方面。公司将授予他 350 万股的股票期权。BetterLife 专注于 BETR-001，这是一种用于治疗神经系统疾病的非致幻性 LSD 衍生物，并正在探索其针对病毒感染的药物候选者的进一步开发机会</p>

<p>Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) (&#34;BetterLife&#34; or the &#34;Company&#34;), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. (&#34;Cybin&#34;) (NYSE: CYBN), as Executive Chairman and Director.</p>
<div class="lb-trans"><p>温哥华，不列颠哥伦比亚省 --（Newsfile Corp. -2026 年 5 月 13 日）- BetterLife Pharma Inc.（CSE: BETR）（OTCQB: BETRF）（FSE: NPAU）（&#34;BetterLife&#34;或&#34;公司&#34;），一家新兴生物科技公司，欣然宣布已任命 Doug Drysdale 为执行董事长和董事，Doug Drysdale 目前是 BetterLife 的企业顾问，曾任 Cybin Inc.（&#34;Cybin&#34;）（NYSE: CYBN）的首席执行官。</p>
</div><p>At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.</p>
<div class="lb-trans"><p>在 Cybin，Drysdale 先生领导了公司的战略和团队建设，使其在短短三年内从分子创始阶段发展到第三阶段临床试验。Drysdale 先生因其在多个演讲、座谈会和媒体采访中积极倡导通过革命性的方法改善心理健康而闻名。</p>
</div><p>&#34;We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored by a track record of executing multiple successful transactions across diverse markets and therapeutic indications, brings a depth of strategic insight and operational expertise that will meaningfully strengthen BetterLife&#34;, said Ahmad Doroudian, CEO of BetterLife. &#34;Doug's experience navigating complex deal environments and scaling opportunities across jurisdictions will be invaluable as we continue to advance our growth strategy and create long-term shareholder value.&#34;</p>
<div class="lb-trans"><p>&#34;我们很高兴欢迎 Doug 加入我们的董事会。他在全球领导力方面的卓越表现，凭借在不同市场和治疗领域成功执行多项交易的记录，带来了深厚的战略洞察力和运营专业知识，这将显著增强 BetterLife 的实力，&#34;BetterLife 的首席执行官 Ahmad Doroudian 表示。&#34;Doug 在复杂交易环境中导航和扩大机会的经验将对我们继续推进增长战略和创造长期股东价值至关重要。&#34;</p>
</div><p>Mr. Drysdale commented, &#34;I am thrilled to join BetterLife as Executive Chairman and Director. Having led Cybin from molecule inception to Phase 3 trials in just three years, I look forward to bringing that same execution focus and global transaction expertise to accelerate BetterLife's growth strategy. Together with the team, we will continue to advance innovative therapies that target neurological disorders and deliver long-term value for patients and shareholders alike.&#34;</p>
<div class="lb-trans"><p>Drysdale 先生评论道：&#34;我很高兴能以执行董事长和董事的身份加入 BetterLife。作为 Cybin 的领导者，我在短短三年内将其从分子创始阶段推进到第三阶段临床试验，我期待将这种执行专注和全球交易专业知识带入 BetterLife，以加速其增长战略。与团队一起，我们将继续推进针对神经系统疾病的创新疗法，为患者和股东创造长期价值。&#34;</p>
</div><p>Pursuant to the appointment of Mr. Drysdale as Executive Chairman, the Company has agreed to grant Mr. Drysdale stock options to purchase 3,500,000 common shares of BetterLife, with an exercise price of $0.065, monthly vesting over 24 months and a ten (10) year term.</p>
<div class="lb-trans"><p>根据 Drysdale 先生被任命为执行董事长的决定，公司已同意授予 Drysdale 先生购买 3,500,000 股 BetterLife 普通股的股票期权，行使价格为 0.065 美元，按月在 24 个月内归属，期限为十（10）年。</p>
</div><p><strong>About BetterLife Pharma</strong></p>
<div class="lb-trans"><p><strong>关于 BetterLife Pharma</strong></p>
</div><p>BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.</p>
<div class="lb-trans"><p>BetterLife Pharma Inc.是一家新兴生物技术公司，主要专注于开发和商业化 BETR-001 以治疗各种神经系统疾病。BETR-001 目前处于临床前和 IND 启用研究阶段，是一种非致幻和非管制的 LSD 衍生物，其独特之处在于它不受监管，因此可以自我管理。BetterLife 对 BETR-001 的合成专利消除了监管障碍，其待批专利涵盖了各种神经系统疾病的治疗，预计有效期至 2042 年左右。</p>
</div><p>BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.</p>
<div class="lb-trans"><p>BetterLife 还拥有一种用于治疗病毒感染的药物候选者，并正在寻求进一步发展的战略选择。</p>
</div><p>For further information, please visit BetterLife Pharma.</p>
<div class="lb-trans"><p>有关更多信息，请访问 BetterLife Pharma。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release may contain forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as &#34;will&#34;, &#34;may&#34;, &#34;should&#34;, &#34;anticipate&#34;, &#34;expects&#34; and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.</p>
<div class="lb-trans"><p>没有证券交易所审查或对本新闻稿内容的充分性或准确性承担责任。本新闻稿可能包含非历史事实的前瞻性声明。前瞻性声明通常通过&#34;将&#34;、&#34;可能&#34;、&#34;应该&#34;、&#34;预期&#34;、&#34;期望&#34;和类似表达来识别。除历史事实声明外，本发布中包含的所有声明均为前瞻性声明，涉及风险和不确定性。不能保证这些声明将被证明是准确的，实际结果和未来事件可能与这些声明中预期的有实质性差异。可能导致实际结果与公司预期有实质性差异的重要因素包括未能满足相关证券交易所的条件以及公司不时向证券监管机构提交的文件中详细列出的其他风险。读者应注意，准备任何前瞻性信息时所使用的假设可能被证明是错误的。事件或情况可能导致实际结果与预测有实质性差异，原因是众多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制范围。读者应谨慎对待任何前瞻性信息。尽管管理层在准备时认为这些信息是合理的，但可能被证明是错误的，实际结果可能与预期有实质性差异。本新闻稿中包含的前瞻性声明明确受到本警示说明的限制。本新闻稿中包含的前瞻性声明是在本新闻稿日期作出的，公司将根据适用法律的明确要求，公开更新或修订任何包含的前瞻性声明。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5696/297144_7bbd785a74da5989_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/5696/297144_7bbd785a74da5989_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297144</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/297144</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297144/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/297144/375"/></p>

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director | BETRF Stock News

StockTitan

博时恒生港股通创新药精选ETF

华夏上证科创板生物医药ETF

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

生物科技ETF基金

创新药

华宝中证制药ETF

华夏中证生物科技主题ETF

华宝恒生港股通创新药精选ETF

博时恒生医疗保健(QDII-ETF)

医疗业 ETF - Vanguard

华泰柏瑞恒生创新药ETF(QDII)

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

华夏医药ETF

医疗业 ETF - SPDR

标普健康医疗设备 ETF - SPDR

易方达中证生物科技主题ETF

汇添富国证港股通创新药ETF

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

易方达沪深300医药ETF

国泰中证生物医药ETF

Cybin

BetterLife Pharma 宣布任命 Doug Drysdale 为执行主席和董事 | BETRF 股票新闻